Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.

[1]  L. Hondeghem.  Estimation of Proarrhythmic Hazards by QT Prolongation/Shortening: QT Obsession? , 2006 .

[2]  Y. Kuryshev,et al.  HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. , 2005, Journal of pharmacological and toxicological methods.

[3]  R. Shah,et al.  Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. , 2005, Heart rhythm.

[4]  Michael C Sanguinetti,et al.  Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.

[5]  Jiesheng Kang,et al.  Discovery of a Small Molecule Activator of the Human Ether-a-go-go-Related Gene (HERG) Cardiac K+ Channel , 2005, Molecular Pharmacology.

[6]  Jamie Goode,et al.  The hERG Cardiac Potassium Channel: Structure, Function and Long QT Syndrome , 2005 .

[7]  K. Sunagawa,et al.  Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. , 2005, Journal of the American College of Cardiology.

[8]  Y. Kuryshev,et al.  Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking , 2005, Journal of Pharmacology and Experimental Therapeutics.

[9]  G. Abbott,et al.  Does hERG Coassemble with a β Subunit? Evidence for Roles of MinK and MiRP1 , 2005 .

[10]  Y. Kuryshev,et al.  HERG channel trafficking. , 2005, Novartis Foundation symposium.

[11]  D. Rosenbaum,et al.  Cellular mechanisms of Torsade de Pointes. , 2005, Novartis Foundation symposium.

[12]  T. McDonald,et al.  Dynamic control of hERG/I(Kr) by PKA-mediated interactions with 14-3-3. , 2005, Novartis Foundation symposium.

[13]  R. Shah,et al.  Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies. , 2005, Novartis Foundation symposium.

[14]  G. Yan,et al.  Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models. , 2004, Journal of electrocardiology.

[15]  C. Antzelevitch.  Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem? , 2004, Journal of electrocardiology.

[16]  Andrew C. Zygmunt,et al.  Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties , 2004, Circulation.

[17]  M. Molimard,et al.  Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. , 2004, Toxicology and applied pharmacology.

[18]  C. Obejero-Paz,et al.  Mechanisms of arsenic-induced prolongation of cardiac repolarization. , 2004, Molecular pharmacology.

[19]  Graeme Milligan,et al.  G Protein-Coupled Receptor Dimerization: Function and Ligand Pharmacology , 2004, Molecular Pharmacology.

[20]  D. Roden.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[21]  Jean-Pierre Valentin,et al.  Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. , 2004, Journal of pharmacological and toxicological methods.

[22]  H. Katus,et al.  Adrenergic regulation of the rapid component of the cardiac delayed rectifier potassium current, IKr, and the underlying hERG ion channel , 2004, Basic Research in Cardiology.

[23]  J. Valentin,et al.  Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes , 2004, Fundamental & clinical pharmacology.

[24]  Gary A Gintant,et al.  The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block , 2004, Journal of cardiovascular pharmacology.

[25]  Todd Wisialowski,et al.  Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. , 2004, European journal of pharmacology.

[26]  S. Nattel,et al.  KvLQT1 Modulates the Distribution and Biophysical Properties of HERG , 2004, Journal of Biological Chemistry.

[27]  D. Escande,et al.  Cardiac channelopathies: from men to mice , 2004, Annals of medicine.

[28]  C. Antzelevitch.  Cellular basis and mechanism underlying normal and abnormal myocardial repolarization and arrhythmogenesis , 2004, Annals of medicine.

[29]  Y. Sawada,et al.  Quantitative Relationship Between Myocardial Concentration of Tacrolimus and QT Prolongation in Guinea Pigs: Pharmacokinetic/Pharmacodynamic Model Incorporating a Site of Adverse Effect , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[30]  Candace S. Brown,et al.  Pharmacokinetic Factors in the Adverse Cardiovascular Effects of Antipsychotic Drugs , 2004, Clinical pharmacokinetics.

[31]  Charles Antzelevitch,et al.  Assessing predictors of drug-induced torsade de pointes. , 2003, Trends in pharmacological sciences.

[32]  D. Roden,et al.  IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  Andreas Ebneth,et al.  HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. , 2003, Current opinion in drug discovery & development.

[34]  B. Fermini,et al.  The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.

[35]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[36]  Baofeng Yang,et al.  Impairment of Human Ether-à-Go-Go-related Gene (HERG) K+ Channel Function by Hypoglycemia and Hyperglycemia , 2003, The Journal of Biological Chemistry.

[37]  Calum A. MacRae,et al.  Drugs That Induce Repolarization Abnormalities Cause Bradycardia in Zebrafish , 2003, Circulation.

[38]  H. Duff,et al.  Selective Knockout of Mouse ERG1 B Potassium Channel Eliminates IKr in Adult Ventricular Myocytes and Elicits Episodes of Abrupt Sinus Bradycardia , 2003, Molecular and Cellular Biology.

[39]  A. Wiseman.  Do unpredictable toxic side-effects of drugs reflect their promiscuous binding energies? , 2003, Trends in pharmacological sciences.

[40]  P. Hoffmann,et al.  Blinded Test in Isolated Female Rabbit Heart Reliably Identifies Action Potential Duration Prolongation and Proarrhythmic Drugs: Importance of Triangulation, Reverse Use Dependence, and Instability , 2003, Journal of cardiovascular pharmacology.

[41]  Jennifer L. Robinson,et al.  Long QT Syndrome. , 2003, JAMA.

[42]  David Taylor.  Ziprasidone in the Management of Schizophrenia , 2003, CNS drugs.

[43]  J. Tamargo,et al.  Effects of levobupivacaine, ropivacaine and bupivacaine on HERG channels: stereoselective bupivacaine block , 2002, British journal of pharmacology.

[44]  A. Cavalli,et al.  Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.

[45]  Gisbert Schneider,et al.  A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries , 2002, Chembiochem : a European journal of chemical biology.

[46]  W. Crumb,et al.  Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.

[47]  D. Noble.  Modeling the Heart--from Genes to Cells to the Whole Organ , 2002, Science.

[48]  E. Zitron,et al.  Rapid component I(Kr) of the guinea-pig cardiac delayed rectifier K(+) current is inhibited by beta(1)-adrenoreceptor activation, via cAMP/protein kinase A-dependent pathways. , 2002, Cardiovascular research.

[49]  M. Weiss,et al.  P-glycoprotein inhibitors enhance saturable uptake of idarubicin in rat heart: pharmacokinetic/pharmacodynamic modeling. , 2002, The Journal of pharmacology and experimental therapeutics.

[50]  P. Hoffmann,et al.  Investigation of the Potential of Clozapine to Cause Torsade de Pointes , 2002, Adverse drug reactions and toxicological reviews.

[51]  G. Breithardt,et al.  Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. , 2002, The Journal of pharmacology and experimental therapeutics.

[52]  A. L. Muzikant,et al.  Models for profiling the potential QT prolongation risk of drugs. , 2002, Current opinion in drug discovery & development.

[53]  T. McDonald,et al.  HERG K+ Channel Activity Is Regulated by Changes in Phosphatidyl Inositol 4,5-Bisphosphate , 2001, Circulation research.

[54]  R. Lux,et al.  T-wave alternans in LQTS: repolarization-rate dynamics from digital 12-lead Holter data. , 2001, Journal of electrocardiology.

[55]  W. Crumb,et al.  Native and cloned ion channels from human heart: laboratory models for evaluating the cardiac safety of new drugs , 2001 .

[56]  P. Kowey,et al.  Phase 2 Early Afterdepolarization as a Trigger of Polymorphic Ventricular Tachycardia in Acquired Long-QT Syndrome: Direct Evidence From Intracellular Recordings in the Intact Left Ventricular Wall , 2001, Circulation.

[57]  M. Wempe.  Quaternary ammonium ions can externally block voltage-gated K+ channels. Establishing a theoretical and experimental model that predicts KDs and the selectivity of K+ over Na+ ions , 2001 .

[58]  G. Gintant,et al.  The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis , 2001, Journal of cardiovascular pharmacology.

[59]  G. Duker,et al.  Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.

[60]  W S Redfern,et al.  Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. , 2001, Cardiovascular research.

[61]  T. Thum,et al.  Cytochrome P450 mono‐oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat , 2000, British journal of pharmacology.

[62]  C Antzelevitch,et al.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.

[63]  W. Crumb,et al.  Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias , 2000, Expert opinion on pharmacotherapy.

[64]  Glenn I. Fishman,et al.  Cyclic AMP regulates the HERG K+ channel by dual pathways , 2000, Current Biology.

[65]  M. Gralinski.  The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development. , 2000, Journal of pharmacological and toxicological methods.

[66]  H. Wellens,et al.  Downregulation of delayed rectifier K(+) currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. , 1999, Circulation.

[67]  M. Arita,et al.  Bepridil differentially inhibits two delayed rectifier K+ currents, IKr and IKs, in guinea‐pig ventricular myocytes , 1999, British journal of pharmacology.

[68]  F. Charpentier,et al.  Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol. , 1999, Cardiovascular research.

[69]  H. Yoshida,et al.  [Tissue penetration properties of macrolide antibiotics--comparative tissue distribution of erythromycin-stearate, clarithromycin, roxithromycin and azithromycin in rats]. , 1999, The Japanese journal of antibiotics.

[70]  D. Roden,et al.  From genes to channels: normal mechanisms. , 1999, Cardiovascular research.

[71]  S. Chung,et al.  Variability of channel subconductance states of the cardiac sodium channel induced by protease. , 1999, Receptors & channels.

[72]  J. Kingma,et al.  Effects of captopril on early and late arrhythmic events in patients treated with thrombolytic therapy for a first anterior myocardial infarction : The continuing story of cats , 1998 .

[73]  C. Sylvén,et al.  Desethylamiodarone prolongation of cardiac repolarization is dependent on gene expression: a novel antiarrhythmic mechanism. , 1998, Journal of cardiovascular pharmacology.

[74]  T. Palomero,et al.  Modulation of human erg K+ channel gating by activation of a G protein‐coupled receptor and protein kinase C , 1998, The Journal of physiology.

[75]  G. Breithardt,et al.  Experimental models of torsade de pointes. , 1998, Cardiovascular research.

[76]  D. Roden.  Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes , 1998, Pacing and clinical electrophysiology : PACE.

[77]  M. Näbauer,et al.  Potassium channel down-regulation in heart failure. , 1998, Cardiovascular research.

[78]  G. Tomaselli,et al.  Sudden Cardiac Death in Heart Failure , 1998 .

[79]  R. Rangno.  Terfenadine therapy: can we justify the risks? , 1997, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[80]  G Duker,et al.  Rhythm anomalies related to delayed repolarization in vivo: influence of sarcolemmal Ca++ entry and intracellular Ca++ overload. , 1996, The Journal of pharmacology and experimental therapeutics.

[81]  R. Glazer,et al.  Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. , 1996, Circulation.

[82]  K. Hartigan-Go,et al.  Stereoselective cardiotoxic effects of terodiline , 1996, Clinical pharmacology and therapeutics.

[83]  M. D’Incalci,et al.  Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia. , 1996, British Journal of Cancer.

[84]  E. Richelson.  Preclinical pharmacology of neuroleptics: focus on new generation compounds. , 1996, The Journal of clinical psychiatry.

[85]  J Weissenburger,et al.  Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. , 1995, Journal of the American College of Cardiology.

[86]  H. Wellens,et al.  Reproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. , 1995, Circulation.

[87]  D. Kass,et al.  Sudden cardiac death in heart failure. The role of abnormal repolarization. , 1994, Circulation.

[88]  L. Carlsson,et al.  Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. , 1993, Cardiovascular research.

[89]  J. Trimmer,et al.  Dexamethasone rapidly induces Kv1.5 K+ channel gene transcription and expression in clonal pituitary cells , 1993, Neuron.

[90]  R. Prineas,et al.  Sex differences in the evolution of the electrocardiographic QT interval with age. , 1992, The Canadian journal of cardiology.

[91]  E. Prystowsky.  Effects of bepridil on cardiac electrophysiologic properties. , 1992, The American journal of cardiology.

[92]  David C. Riley,et al.  Prolongation of the QT Interval by Volatile Anesthetics in Chronically Instrumented Dogs , 1988, Anesthesia and analgesia.

[93]  R. Bayer,et al.  Basic mechanisms underlying prenylamine-induced 'torsade de pointes': differences between prenylamine and fendiline due to basic actions of the isomers. , 1988, Current medical research and opinion.

[94]  R. Aronson.  Afterpotentials and Triggered Activity in Hypertrophied Myocardium from Rats with Renal Hypertension , 1981, Circulation research.